Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 53179-13-8 | Product Number: P1871
Pirfenidone
Purity: >98.0%(GC)
Synonyms:
- 5-Methyl-1-phenyl-2-pyridone
Product Documents:
Size | Unit Price | Belgium | Japan* | Quantity |
---|---|---|---|---|
100MG |
€44.00
|
Contact Us | 34 |
|
1G |
€282.00
|
2 | 37 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Product Number | P1871 |
Purity / Analysis Method | >98.0%(GC) |
Molecular Formula / Molecular Weight | C__1__2H__1__1NO = 185.23 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
CAS RN | 53179-13-8 |
Reaxys Registry Number | 1526549 |
PubChem Substance ID | 125307545 |
MDL Number | MFCD00866047 |
Specifications
Appearance | White to Light yellow to Green powder to crystal |
Purity(GC) | min. 98.0 % |
Melting point | 107.0 to 111.0 °C |
Properties (reference)
Melting Point | 109 °C |
GHS
Pictogram | |
Signal Word | Warning |
Hazard Statements | H302 : Harmful if swallowed. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
RTECS# | UV1148200 |
Transport Information:
HS Number | 2933399990 |
Application
Pirfenidone: A Unique Antifibrotic and Anti-Inflammatory Agent
References
- 1)The first reports of pirfenidone as an anti-inflammatory agent
- a)S. M. Gadekar, U.S. Patent 3839346, 1974.
- b)S. M. Gadekar, U.S. Patent 3974281, 1976.
- c)S. M. Gadekar, Jpn. Kokai Tokkyo Koho S49-87677, 1974.
- d)S. M. Gadekar, Jpn. Kokai Tokkyo Koho S51-128437, 1976.
- 2)Unique anti-inflammatory properties of pirfenidone
- 3)The first reports of pirfenidone as an antifibrotic agent
- a)H. Suga, S. Teraoka, K. Ota, S. Komemushi, S. Furutani, S. Yamauchi, S. B. Margolin, Exp. Toxic. Pathol. 1995, 47, 287
- b)S. N. Iyer, J. S. Wild, M. J. Schiedt, D. M. Hyde, S. B. Margolin, S. N. Giri, J. Lab. Clin. Med. 1995, 125, 779.
- c)J. P. Kehrera, S. B. Margolin, Toxicol. Lett. 1997, 90, 125.
- 4)The antifibrotic activity of pirfenidone in various organs
- a)S. N. Iyer, G. Gurujeyalakshmi, S. N. Giri, J. Pharmacol. Exp. Ther. 1999, 291, 367.
- b)G. Miric, C. Dallemagne, Z. Endre, S. Margolin, S. M. Taylor, L. Brown, Br. J. Pharmacol. 2001, 133, 687.
- c)H. Oku, T. Shimizu, T. Kawabata, M. Nagira, I. Hikita, A. Ueyama, S. Matsushima, M. Torii, A. Arimura, Eur. J. Pharmacol. 2008, 590, 400.
- d)C. J. Schaefer, D. W. Ruhrmund, L. Pan, S. D. Seiwert, K. Kossen, Eur. Respir. Rev. 2011, 20, 85.
- e)K. Hisatomi, H. Mukae, N. Sakamoto, Y. Ishimatsu, T. Kakugawa, S. Hara, H. Fujita, S. Nakamichi, H. Oku, Y. Urata, H. Kubota, K. Nagata, S. Kohno, BMC Pulm. Med. 2012, 12, 24.
- 5)Reviews
- a) Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib
- B. A. Karimi-Shah, B. A. Chowdhury, N. Engl. J. Med. 2015, 372, 1189.
- b) Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis
- E. S. Kim, G. M. Keating, Drugs 2015, 75, 219.
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.